An increased incidence of cerebrovascular adverse events (e.g. stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs. A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs (manage with immediate discontinuation and close monitoring). Tardive dyskinesia can develop in patients treated with lurasidone (discontinue if clinically appropriate). Atypical antipsychotic drugs have been associated with metabolic changes (hyperglycemia, dyslipidemia, and weight gain) that may increase cardiovascular/cerebrovascular risk. Prolactin elevations may occur. Leukopenia, neutropenia, and agranulocytosis have been reported with antipsychotics (in patients with a pre-existing low white blood cell count (WBC) or history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and this should be discontinued at the first sign of a decline in WBC in the absence of other causative factors). Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment (caution in patients with known cardiovascular or cerebrovascular disease, and in antipsychotic-naïve patients). Use cautiously in patients with history of seizures or with conditions that lower the seizure threshold. Lurasidone has the potential to impair judgment, thinking or motor skills (use caution when operating machinery). The possibility of a suicide attempt is inherent in schizophrenia (closely supervise high-risk patients). Esophageal dysmotility and aspiration have been associated with antipsychotic drug use (should not be used in patients at risk for aspiration pneumonia).